98%
921
2 minutes
20
The gut-brain axis (GBA) plays a significant role in various neurodegenerative disorders, such as Alzheimer's disease (AD), and the gut microbiome (GM) can bidirectionally communicate with the brain through the GBA. Thus, recent evidence indicates that the GM may affect the pathological features and the progression of AD in humans. The aim of our study was to elucidate the impact of probiotics on the pathological features of AD in a 5xFAD model. Probiotics (, , and ) were orally administered in 5xFAD mice to modify the GM composition. Additionally, freeze-dried food containing phosphatidylserine was used as the positive control. Behavioral pathogenesis was assessed through the cross maze and Morris water maze tests. Our findings revealed that probiotic administration resulted in significant improvements in spatial and recognition memories. Furthermore, the neuroprotective effects of probiotics were substantiated by a reduction in amyloid-β accumulation in critical brain regions. Microglial activation in 5xFAD mice was also attenuated by probiotics in the hippocampus and cerebral cortex. Moreover, elevated tau phosphorylation in 5xFAD mice was ameliorated in the probiotics-treated group. The results highlight the potential use of probiotics as a neuroprotective intervention in AD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10968487 | PMC |
http://dx.doi.org/10.3390/brainsci14030208 | DOI Listing |
Biomed Pharmacother
September 2025
Department of Pharmacology, College of Dentistry, Jeonbuk National University, Jeonju 54896, Republic of Korea. Electronic address:
Alzheimer's disease (AD) is marked by amyloid-beta (Aβ) plaque buildup, tau hyperphosphorylation, neuroinflammation, neuronal loss, and impaired adult hippocampal neurogenesis (AHN). Taurine has shown protective effects in various cellular and animal models of AD, though the molecular mechanisms of free taurine and its effects in patient-derived models remain underexplored. This study evaluates taurine's therapeutic potential using integrated in silico, in vitro, in vivo, and ex vivo approaches.
View Article and Find Full Text PDFFront Aging Neurosci
August 2025
Laboratory of Molecular Neurodegeneration, Graduate School of Biomedical Systems and Technologies, Institute of Biomedical Systems and Biotechnology, Peter the Great St. Petersburg Polytechnic University, Saint Petersburg, Russia.
Alzheimer's disease (AD) is a neurodegenerative disorder that leads to progressive cognitive decline and significant disruptions in hippocampal neural networks, critically impacting memory and learning. Understanding the neural mechanisms underlying these impairments is essential for developing effective therapies. The 5xFAD mouse model, known for progressive neurodegeneration and cognitive deficits, provides a valuable platform for investigating associative learning and memory impairments related to AD.
View Article and Find Full Text PDFRedox Biol
August 2025
i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Porto, Portugal; IBMC - Instituto de Biologia Molecular e Celular, Porto, Portugal; Departamento de Biomedicina - Unidade de Biologia Experimental, Faculdade de Medicina da Universidade do Porto, Porto, Portugal. Elec
Despite clear evidence that vitamin C levels are depleted in the brains of Alzheimer's disease (AD) patients, dietary supplementation has consistently failed in clinical trials, suggesting a critical bottleneck not in systemic supply, but in its transport into brain cells. Here, we identify this bottleneck as a progressive downregulation of the ascorbate transporter, Slc23a2, also known as SVCT2, in microglia. Then we hypothesized that bypassing this cellular deficiency via targeted SVCT2 overexpression in microglia could either prevent the onset of pathology or rescue established functional deficits.
View Article and Find Full Text PDFCell Rep
August 2025
Department of Immunology, University of Toronto, Toronto, ON, Canada; Buck Institute for Research in Aging, Novato, CA, USA; Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA; Division of Cellular & Molecular Biology, Toronto General Hospital Research Insti
The "gut-brain axis" is an emerging target in Alzheimer's disease (AD), although its immunological features remain poorly understood. Using single-cell RNA sequencing, coupled to extensive spectral-tuning flow cytometry validation of the colon immune compartment in the 5XFAD amyloid-β mouse model, we found several AD-associated changes including in B/plasma cell activity. Notably, levels of CXCR4 antibody-secreting cells are reduced in 5XFAD colons.
View Article and Find Full Text PDFMol Psychiatry
August 2025
Department of Neurobiology, Interdisciplinary Center for Neuroscience (IZN), Heidelberg University, Heidelberg, Germany.
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, characterized by cognitive decline and neuronal degeneration. The formation of amyloid β plaques and neurofibrillary tangles are key morphological features of AD pathology. However, the specific molecules responsible for the cell destruction triggered by amyloid β and tau proteinopathies in AD has not yet been identified.
View Article and Find Full Text PDF